IDEAYA Biosciences (IDYA) is back in focus after outlining an FDA backed registrational plan for IDE849, its DLL3 targeted antibody drug conjugate in difficult neuroendocrine and small cell lung cancers. Against this clinical backdrop, IDEAYA Biosciences has seen momentum cool, with the share price down 9.72% over the past day and 16.56% over 30 days, contributing to a 29.48% decline over 90 days and a 19.03% year to date share price fall. However, the 5 year total shareholder return of...
Ideaya Biosciences is continuing to advance its first-in-class, oral, small-molecule protein kinase C [PKC] inhibitor darovasertib. I rate IDYA stock as Strong Buy.
Stifel restarts IDEAYA coverage: darovasertib + crizotinib may become uveal melanoma standard of care. Read more here.
Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]
--IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three...
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year
IDEAYA Biosciences (IDYA) said Monday it held a US Food and Drug Administration meeting on the desig
This is the newest page. Registered accounts read further back.